☆ 4.7 Article

Transitioning to active-controlled trials to evaluate cardiovascular safety and efficacy of medications for type 2 diabetes

CARDIOVASCULAR DIABETOLOGY (2022)

Related references

Note: Only part of the references are listed.

Review Endocrinology & Metabolism

Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis

Thomas Karagiannis et al.

Summary: This study conducted a systematic review and meta-analysis to evaluate the efficacy and safety of tirzepatide for type 2 diabetes. The results showed that tirzepatide had dose-dependent superiority in lowering HbA(1c) and reducing body weight compared to placebo, GLP-1 RAs, and basal insulin. However, tirzepatide was associated with an increased incidence of gastrointestinal adverse events.

DIABETOLOGIA (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis

Naveed Sattar et al.

Summary: This meta-analysis study on Tirzepatide included 7 randomized controlled trials, and the findings suggest that using Tirzepatide in patients with T2D does not increase the risk of major cardiovascular events.

NATURE MEDICINE (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes A Meta-analysis

Darren K. McGuire et al.

Summary: SGLT2 inhibitors were found to reduce the risk of major adverse CV events and showed significant heterogeneity in associations with CV death. The most consistent benefit of this class of drugs was a reduction in risk for heart failure and kidney outcomes, with heart failure risk reduction being the most consistent observation across the trials.

JAMA CARDIOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease

Deepak L. Bhatt et al.

Summary: The trial involving 10,584 patients with diabetes and chronic kidney disease showed that sotagliflozin resulted in fewer deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure compared to placebo. However, there were adverse events such as diarrhea, mycotic infections, and diabetic ketoacidosis associated with sotagliflozin.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure

Deepak L. Bhatt et al.

Summary: In patients with diabetes and recent worsening heart failure, treatment with sotagliflozin significantly reduced the total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure compared to placebo, regardless of the timing of administration.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

Stefano Del Prato et al.

Summary: In this study comparing Tirzepatide and glargine in patients with type 2 diabetes inadequately controlled on oral glucose-lowering medications, Tirzepatide demonstrated greater reduction in HbA(1c) and lower incidence of hypoglycemia at week 52, with no excess cardiovascular risk observed compared to glargine.

LANCET (2021)

Add to Collection

Review Endocrinology & Metabolism

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials

Naveed Sattar et al.

Summary: The meta-analysis showed that GLP-1 receptor agonists can reduce the risk of major adverse cardiovascular events, all-cause mortality, hospital admission for heart failure, and worsening kidney function in patients with type 2 diabetes, regardless of structural homology.

LANCET DIABETES & ENDOCRINOLOGY (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD

Francesco Cosentino et al.

EUROPEAN HEART JOURNAL (2020)

Add to Collection

Article Endocrinology & Metabolism

Glycemic Targets: Standards of Medical Care in Diabetes-2020

DIABETES CARE (2020)

Add to Collection

Article Endocrinology & Metabolism

2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

John B. Buse et al.

DIABETOLOGIA (2020)

Add to Collection

Article Cardiac & Cardiovascular Systems

2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes

Sandeep R. Das et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein et al.

LANCET (2019)

Add to Collection

Article Medicine, General & Internal

Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Mansoor Husain et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Medicine, General & Internal

Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial

Julio Rosenstock et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)

Add to Collection

Review Endocrinology & Metabolism

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

Soren L. Kristensen et al.

LANCET DIABETES & ENDOCRINOLOGY (2019)

Add to Collection

Article Medicine, General & Internal

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Adrian F. Hernandez et al.

LANCET (2018)

Add to Collection

Article Medicine, General & Internal

Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes

Steven P. Marso et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Medicine, General & Internal

Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes

Rury R. Holman et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Endocrinology & Metabolism

Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA. IT): a randomised, multicentre trial

Olga Vaccaro et al.

LANCET DIABETES & ENDOCRINOLOGY (2017)

Add to Collection

Article Medicine, General & Internal

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Steven P. Marso et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Article Medicine, General & Internal

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

Steven P. Marso et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Article Medicine, General & Internal

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Bernard Zinman et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Article Medicine, General & Internal

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome

Marc A. Pfeffer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Article Multidisciplinary Sciences

Edoxaban in the Evolving Scenario of Non Vitamin K Antagonist Oral Anticoagulants Imputed Placebo Analysis and Multiple Treatment Comparisons

Paolo Verdecchia et al.

PLOS ONE (2014)

Add to Collection

Article Medicine, General & Internal

Edoxaban versus Warfarin in Patients with Atrial Fibrillation

Robert P. Giugliano et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

Add to Collection

Article Medicine, General & Internal

Apixaban versus Warfarin in Patients with Atrial Fibrillation

Christopher B. Granger et al.

NEW ENGLAND JOURNAL OF MEDICINE (2011)

Add to Collection

Article Medicine, General & Internal

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

Manesh R. Patel et al.

NEW ENGLAND JOURNAL OF MEDICINE (2011)

Add to Collection

Article Medicine, General & Internal

Dabigatran versus Warfarin in Patients with Atrial Fibrillation.

Stuart J. Connolly et al.

NEW ENGLAND JOURNAL OF MEDICINE (2009)

Add to Collection

Article Cardiac & Cardiovascular Systems

Cardiovascular disease and type 2 diabetes mellitus: Regulating glucose and regulating drugs

M. Odette Gore et al.

Current Cardiology Reports (2009)

Add to Collection

Article Mathematical & Computational Biology

Some fundamental issues with non-inferiority testing in active controlled trials

HMJ Hung et al.

STATISTICS IN MEDICINE (2003)

Add to Collection

Article Mathematical & Computational Biology

Design and analysis of non-inferiority mortality trials in oncology

M Rothmann et al.

STATISTICS IN MEDICINE (2003)

Add to Collection

Article Health Care Sciences & Services

Statistical methods for comparison to placebo in active-control trials

V Hasselblad et al.

DRUG INFORMATION JOURNAL (2001)

Add to Collection

© Peeref 2019-2024. All rights reserved.